JNJ - Johnson

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Johnson & Johnson raises 2025 sales guidance by $2B and targets $50B oncology sales by 2030 amid robust Q2 performance
• J&J rallies big pharma after earnings despite Trump’s latest tariff threat
• 4 stocks to watch on Wednesday: GS, MS, JNJ, BAC
• J&J boosts full-year outlook on forex tailwinds and operational performance
• Earnings Snapshot: Johnson & Johnson surpasses Q2 estimates; raises FY25 outlook above consensus
• Johnson & Johnson's Charts: Innovative Medicine +5% Y/Y in Q2 led by 23% rise in DARZALEX
• Johnson & Johnson declares $1.30 dividend
• Johnson & Johnson Non-GAAP EPS of $2.77 beats by $0.09, revenue of $23.7B beats by $840M
• Trump eyes drug, chip tariffs by month-end
• Johnson & Johnson Q2 Preview: Focus on tariff threat, MedTech softness
• Short bets against S&P 500 healthcare stocks climb in June; MRNA tops list again
• Earnings week ahead: JPM, BAC, GS, MS, C, JNJ, TSM, ABT, PEP, MMM, SLB, UAL, NFLX, and more
• FDA mulls faster drug reviews in exchange for lower prices in U.S.- Bloomberg
• FDA publishes more than 200 rejection letters in a bid to improve transparency
• J&J wins appeals court ruling against Teva and Viatris in patent dispute over neuro drug
• Trump mulls 200% tariff on pharmaceuticals
• Johnson & Johnson seeks FDA nod for expanded use of Caplyta
• Leaked memo reportedly shows biotech lobby group’s opposition to RFK Jr.
• US judge halts Trump administration move to layoff HHS employees
• Bristol Myers, Gilead, J&J, Novartis win favorable FDA label updates for cell therapies